CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
about
The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosisChildhood obesity, bone development, and cardiometabolic risk factorsStructure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosisRelationship between serum RANKL and RANKL in boneGout increases risk of fracture: A nationwide population-based cohort study.Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatasesNo significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one yearThe ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.Novel therapeutic targets in myeloma bone disease.Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosisMore powerful haplotype sharing by accounting for the mode of inheritance.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisProspective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.Osteoporosis syndrome in thalassaemia major: an overview.Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenzAlcoholism: a systemic proinflammatory condition.Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus.HIV-1 protein induced modulation of primary human osteoblast differentiation and function via a Wnt/β-catenin-dependent mechanism.The genetics of bone loss: challenges and prospectsNephrolithiasis-associated bone disease: pathogenesis and treatment options.Serum osteoprotegerin levels are related to height loss: the Tromsø Study.Breast Cancer: Rank Ligand Inhibition.The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesisDenosumab for the treatment of bone metastases in breast cancer: evidence and opinionNCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A.Osteoprotegerin Regulates Pancreatic β-Cell Homeostasis upon Microbial InvasionChanges in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.Secretion patterns of circulating osteoprotegerin and response to acute and chronic energy deprivation in young healthy adults.Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblastsHigher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with OsteopeniaBone turnover markers in patients with type 1 Gaucher disease.Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional linksOsteoporosis and polymorphisms of osteoprotegerin gene in postmenopausal women - a pilot study.Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individualsAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.OPG rs2073617 polymorphism is associated with upregulated OPG protein expression and an increased risk of intervertebral disc degeneration
P2860
Q26780523-FCF82DE9-81EC-4543-B07D-71C18D4C4F93Q26853091-3604BBF7-F25F-4C33-A33B-91325C4ACC30Q27665673-02C85B0A-8C55-46D2-8E12-7F42A6A9CE15Q28245828-E3451E97-B252-4200-8C12-491F49F31040Q33590612-F2498F77-C45E-4D60-9845-C33B0401FA62Q33636430-B27FB24D-4C82-4890-AA10-DCD368B8E6BBQ33638583-A47AD9B2-221E-4827-86B1-F1347B8DB2F3Q33781943-6313B9A8-ECB0-4BBF-91FC-FD476AE63D8AQ34025065-5A06AD31-0F6F-47E6-8852-E473BDC273B7Q34069299-18EED080-E307-49E3-A3D4-DE35B84A3A61Q34076338-1793CB66-C9AD-41B7-8634-C6B1312F1C40Q34158441-6982F16F-D281-4C07-B660-9056025F1CE8Q34158739-1D056C43-71F8-4B48-A90F-CE440AB058CEQ34211460-4A529AAA-9F0E-4631-A059-4F4083A47FF7Q34248604-A2916AB3-8EEE-4629-A23A-1360A76E4282Q34405036-D9A85853-4E4D-44BB-852F-910CBFC26512Q34417248-3A3499D5-954B-4A6C-AC53-DD78C475FE76Q34457946-176B07B3-07C4-4CED-AD52-AA93D854D441Q34529322-30ECA6FA-9FBE-4C51-95F0-B99DF7B73CE4Q34894261-B32F2572-316D-4461-82F0-1F8733AEA4D3Q34936324-45E818C0-0B1F-4B1D-8D0A-61DC6A6176D2Q34940502-C8F043BB-810A-4F3C-9046-D528167BFC2DQ35095558-C6E50AA7-2F1A-4AF8-87E4-552FAA9FD5E9Q35140845-B3B9D9C5-4518-4AB4-B2AE-C42C64196E5EQ35205280-3F85DD28-F9CA-4BA7-83CE-55B6B78A26CDQ35563274-BF0F2070-5829-4ECF-A075-0F682637BAB0Q35756761-8E9E7527-ED10-4859-BE9E-618302A2F22CQ35818302-9CC9D6DB-F733-4CFE-9FFC-E3F1EF2F7E8CQ35890262-1455B70C-E1CD-4211-8063-4772DDABD099Q36078749-52F83690-84F2-4914-9C61-B8BFC8939578Q36134703-C56C4C93-2B9A-487C-88C8-D4FE46E22CBAQ36293557-39D21866-CBF3-4015-9DBF-E4A179D69D6CQ36305260-7B5923BF-6769-46A7-B751-8F0E5420447AQ36562916-F14F1A27-9098-4BC0-9056-27E44640DA47Q36648170-772D62A8-7CF9-4F09-84C9-4C82B55F7EC3Q36842511-3CA13A35-47F6-49FA-9939-BF07CB136BD3Q36958022-48E850B5-082D-4C19-B5BD-77E00C6A481FQ36959809-A9BD365F-095C-4175-B78E-97652C65D4D1Q37099010-982B852B-02C3-4838-B64E-7C6C1EF141F5Q37107900-844F5D3C-470A-49B3-BB6C-5711FC1E6374
P2860
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CLINICAL Review #: the role of ...... egerin: clinical implications.
@en
type
label
CLINICAL Review #: the role of ...... egerin: clinical implications.
@en
prefLabel
CLINICAL Review #: the role of ...... egerin: clinical implications.
@en
P2093
P356
P1476
CLINICAL Review #: the role of ...... egerin: clinical implications.
@en
P2093
Damaris Vega
Khashayar Sakhaee
Naim M Maalouf
P304
P356
10.1210/JC.2007-0646
P407
P577
2007-09-25T00:00:00Z